Registration Dossier

Administrative data

Description of key information

The following studies are available for the acute toxicity endpoint:
Acute Toxicity Oral.001: LD50 (rat)=5,000 mg/kg bw
Acute Toxicity Inhalation.001: LC50 (rat)>38.6 mg/l/4 hour
Acute Toxicity Dermal.001: LD50 (rat)>20,000 mg/kg bw

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Dose descriptor:
LD50
5 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion
Dose descriptor:
LC50
38.6 mg/m³

Acute toxicity: via dermal route

Endpoint conclusion
Dose descriptor:
LD50
20 000 mg/kg bw

Additional information

CBM was not acutely toxic by the oral, dermal or inhalation routes. The rat oral LD50 > 5000 mg/kg bw. The rabbit dermal LD50 was > 20,000 mg/kg bw. The rat inhalationLC50 was >38.6 mg/l/4hours.

 

Justification for classification or non-classification

Based upon the LD50 values for oral and dermal exposure, and the LC50 value for inhalation exposure and the absence of other major significant effects, CBM does not need to be classified for acute toxicity according to Directive 67/548/EEC or Regulation (EC) No 1272/2008.